Reuters logo
7 months ago
BRIEF-Immunomedics achieves patient enrollment for single-arm Phase 2 study with sacituzumab govitecan
December 27, 2016 / 12:15 PM / 7 months ago

BRIEF-Immunomedics achieves patient enrollment for single-arm Phase 2 study with sacituzumab govitecan

1 Min Read

Dec 27 (Reuters) - Immunomedics Inc

*

* Immunomedics announces achievement of patient enrollment into single-arm phase 2 study with sacituzumab govitecan (immu-132) in triple-negative breast cancer

* Mid-2017 submission of biologics license application (bla) for accelerated approval progressing as planned Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below